We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
-9.7%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$1.22B
AUM Growth
-$882M
Cap. Flow
-$698M
Cap. Flow %
-57.3%
Top 10 Hldgs %
37.48%
Holding
87
New
26
Increased
14
Reduced
19
Closed
26

Top Buys

Rank Stock Value
1
MCK icon
McKesson
MCK
+$50.4M
2
ABBV icon
AbbVie
ABBV
+$47.5M
3
HRTX icon
Heron Therapeutics
HRTX
+$46.7M
4
CAH icon
Cardinal Health
CAH
+$45.6M
5
BDX icon
Becton Dickinson
BDX
+$38.3M

Top Sells

Rank Stock Value
1
BOLD
Audentes Therapeutics, Inc
BOLD
+$73.8M
2
NVRO
NEVRO CORP.
NVRO
+$67.8M
3
ZBH icon
Zimmer Biomet
ZBH
+$66.3M
4
GILD icon
Gilead Sciences
GILD
+$55.2M
5
AGN
Allergan plc
AGN
+$53.8M

Sector Composition

Rank Sector Weight
1 Healthcare 84.43%
2 Technology 3.14%
3 Consumer Discretionary 1.97%
4 Industrials 0.46%
5 Utilities 0.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALXN
1
DELISTED
Alexion Pharmaceuticals
ALXN
$61.6M 5.06%
686,249
-390,193
-36% -$38.3M
ABBV icon
2
AbbVie
ABBV
$458B
$55.2M 4.53%
724,174
+557,935
+336% +$47.5M
ELV icon
3
Elevance Health
ELV
$81.9B
$50.8M 4.18%
223,925
+25,377
+13% +$6.92M
MCK icon
4
McKesson
MCK
$98.5B
$46.5M 3.82%
+343,950
New +$50.4M
CAH icon
5
Cardinal Health
CAH
$53.4B
$42.1M 3.46%
+878,531
New +$45.6M
GILD icon
6
Gilead Sciences
GILD
$161B
$41.4M 3.4%
553,339
-798,397
-59% -$55.2M
ICUI icon
7
ICU Medical
ICUI
$3.93B
$40.8M 3.35%
202,339
+36,674
+22% +$7.06M
PFE icon
8
Pfizer
PFE
$140B
$38.5M 3.17%
1,244,414
+271,439
+28% +$9.25M
KRTX
9
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$36M 2.95%
499,510
-103,041
-17% -$8.81M
BDX icon
10
Becton Dickinson
BDX
$43.1B
$34.7M 2.85%
+154,929
New +$38.3M
CI icon
11
Cigna
CI
$76.6B
$34.5M 2.83%
194,690
-71,027
-27% -$13.8M
AERI
12
DELISTED
Aerie Pharmaceuticals
AERI
$34.1M 2.8%
2,528,276
+114,812
+5% +$2.18M
BMRN icon
13
BioMarin Pharmaceuticals
BMRN
$11.5B
$33.8M 2.77%
399,605
-154,029
-28% -$13.3M
HUM icon
14
Humana
HUM
$46.7B
$32.4M 2.66%
103,030
+23,484
+30% +$7.92M
ARNA
15
DELISTED
Arena Pharmaceuticals Inc
ARNA
$31.5M 2.58%
749,217
-321,399
-30% -$14.7M
COR icon
16
Cencora
COR
$60.3B
$30M 2.46%
+338,732
New +$29.8M
HRTX icon
17
Heron Therapeutics
HRTX
$86.3M
$29.1M 2.39%
+2,481,917
New +$46.7M
UNH icon
18
UnitedHealth
UNH
$382B
$26.1M 2.14%
104,722
+10,023
+11% +$2.76M
BIIB icon
19
Biogen
BIIB
$29.9B
$25.6M 2.11%
81,013
-147,315
-65% -$44.7M
BAX icon
20
Baxter International
BAX
$11.6B
$25.1M 2.06%
+309,635
New +$26.7M
VRTX icon
21
Vertex Pharmaceuticals
VRTX
$121B
$22.7M 1.87%
95,482
+38,560
+68% +$8.85M
EW icon
22
Edwards Lifesciences
EW
$47.6B
$22.3M 1.83%
355,176
+45,339
+15% +$3.27M
JNJ icon
23
Johnson & Johnson
JNJ
$635B
$21.8M 1.79%
+166,375
New +$23.6M
PEN icon
24
Penumbra
PEN
$12.5B
$19.1M 1.57%
118,190
-300,602
-72% -$50.6M
IRTC icon
25
iRhythm Holdings
IRTC
$3.59B
$19M 1.56%
233,409
-224,832
-49% -$18.6M
1
2 3 4

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
PRS
Pinkerton Retirement Specialists Coeur D Alene, Idaho $1.1B AUM 30.57% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
CF
Corebridge Financial Houston, Texas $1.09B AUM 1.85% 1-Year Est. Return
MIA
MMBG Investment Advisors Miami, Florida $1.09B AUM 30.96% 1-Year Est. Return

PFM Health Sciences's Q1 2020 Portfolio in Review

As of Q1 2020, PFM Health Sciences held 87 positions worth $1.22B, down 42% from $2.1B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

PFM Health Sciences withdrew a net $698M in Q1 2020, closing 26 positions and reducing 19 holdings. Its most notable exit was Audentes Therapeutics, Inc, an estimated $73.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 70% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, PFM Health Sciences opened a new position in McKesson worth $46.5M.

  • PFM Health Sciences's largest Q1 2020 buy was McKesson: 343,950 shares worth $46.5M.
  • PFM Health Sciences added most to AbbVie in Q1 2020, an estimated $47.5M increase.
  • PFM Health Sciences's biggest Q1 2020 reduction was Gilead Sciences, cutting an estimated $55.2M.
  • PFM Health Sciences fully exited Audentes Therapeutics, Inc in Q1 2020, selling an estimated $73.8M.
  • PFM Health Sciences's ten largest holdings make up 37% of its $1.22B portfolio in Q1 2020.
  • PFM Health Sciences opened 26 new positions and closed 26 in Q1 2020.
  • PFM Health Sciences's portfolio value fell 42% quarter-over-quarter to $1.22B.

Based on PFM Health Sciences's 13F filing for Q1 2020, filed 15 May 2020.